Main Uses and Therapeutic Intent

Alores is an antihistamine medication primarily used to manage symptoms associated with allergic conditions. It contains the active substance desloratadine, which is a long-acting antagonist of peripheral histamine H1-receptors. By blocking these receptors, the medication prevents histamine—a chemical released by the body during an allergic reaction—from affecting the tissues, thereby reducing common allergy symptoms.

Allergic Rhinitis

The medication is used to relieve symptoms associated with allergic rhinitis, which is inflammation of the nasal passages caused by allergens such as pollen, dust mites, or animal dander. These symptoms typically include:

• Sneezing
• Nasal discharge (runny nose)
• Nasal itching
• Itching of the palate
• Red, itchy, or watery eyes

Alores is indicated for both seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis, which occurs year-round.

Urticaria

Alores is also utilized for the relief of symptoms associated with urticaria, commonly known as hives. This is a skin condition characterized by the appearance of itchy red bumps or wheals. The therapeutic objective in these cases is to reduce:

• Skin itching
• The size and number of hives or wheals

Benefits and Clinical Impact

The primary benefit of this treatment is the improvement of quality of life by reducing the physical discomfort and sleep disturbances often caused by persistent allergic symptoms.

Non-Sedating Profile

As a second-generation antihistamine, desloratadine is designed to have a limited ability to cross the blood-brain barrier. At recommended therapeutic doses, it typically does not cause drowsiness or interfere with psychomotor performance in the majority of users, allowing for the management of symptoms during daily activities.

Duration of Action

The pharmacological profile of the medication allows for a sustained effect. A single dose is generally sufficient to provide relief from symptoms for a full 24-hour period, which supports a consistent reduction in allergic inflammation throughout the day and night.

Regulatory References

1. European Medicines Agency overview

Contraindications and Absolute Restrictions

Alores is absolutely contraindicated and must not be used by any patient with a known allergy or hypersensitivity to the active ingredient desloratadine, any component of the formulation, or the parent compound, loratadine. This is an essential exclusion for all population groups, as defined by regulatory labeling.

Age Group Eligibility

The medicine is officially approved for use in adults and adolescents ge 12 years of age. For pediatric patients, the oral solution is approved starting at 6 months of age for Chronic Idiopathic Urticaria and Perennial Allergic Rhinitis, and ge 2 years for Seasonal Allergic Rhinitis. The safety and efficacy of the tablet formulation are generally not established in children under 12 years of age. Older adults (ge 65 years) should use the medicine with caution due to the higher likelihood of underlying renal or hepatic problems.

Conditional Use and Restrictions

Use is subject to caution and possible dosage adjustment for adult patients with known hepatic (liver) impairment or renal (kidney) impairment. Specific dosage recommendations cannot be made for children who have these conditions due to a lack of available study data. Furthermore, use is generally not recommended for women who are pregnant or breastfeeding, as the drug is excreted into breast milk and safe use during these periods has not been established.

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Alores (Desloratadine), based strictly on government regulatory documents.

Interaction Scope

Category	Official Regulatory Statement
Specific interacting medicines (if explicitly listed):	Erythromycin (Macrolide Antibiotic) and Ketoconazole (Antifungal Azole) are the agents listed in formal interaction trials.
Mechanistic basis of interactions (only if stated in label):	A Pharmacokinetic Interaction occurs, measurably increasing the plasma concentrations ( C max and AUC) of desloratadine and its active metabolite.
Timing-based interaction rules (if applicable):	Food: No timing separation is required; co-ingestion with food has no effect on the systemic bioavailability of the drug.

Interaction Classifications (High-Level)

Classification Type	Official Regulatory Statement
Interaction severity classification:	The measured pharmacokinetic changes with Erythromycin and Ketoconazole are classified by regulatory agencies as "not clinically relevant" in terms of safety.
Interaction-related restrictions:	Alcohol: Formal trials showed no potentiation of the performance-impairing effects of alcohol. However, regulatory documents note that post-marketing surveillance includes reports of alcohol intolerance and intoxication.

Resulting Interaction Structure

Official documents define Alores as having a limited interaction profile. The most salient findings are pharmacokinetic changes—a measurable increase in desloratadine exposure when co-administered with Ketoconazole or Erythromycin—but these changes are assessed as not clinically relevant to the overall safety profile. Furthermore, the label confirms the systemic exposure is not affected by food, and there is no potentiation of alcohol's CNS-impairing effects documented in clinical trials.

Alores functions as a selective antagonist at the 5-hydroxytryptamine type 3 (5-HT3 ) receptor. This biological target is a ligand-gated ion channel expressed on enteric neurons within the gastrointestinal tract and on central nervous system afferent pathways.

By occupying and blocking the 5-HT3 receptor, Alores prevents the binding and subsequent action of endogenous serotonin ( 5-HT). This action inhibits the 5-HT-mediated depolarization of afferent neurons.

Intracellularly, the blockade suppresses the rapid influx of non-selective cations, mitigating the neuronal excitation cascade. Downstream, this modulation alters the signaling dynamics between the enteric nervous system and the central nervous system.

At a system-level, the consequence is a generalized reduction in basal gastrointestinal motility and a prolongation of colonic transit time, coupled with an enhancement of basal water and sodium absorption across the intestinal lumen.

How to Use Alores: Official Administration Guidelines

Alores (desloratadine) is administered exclusively through the oral route and is available in formulations including film-coated tablets, oral solution, and orally disintegrating tablets (ODT). The medicine can be taken without regard to meals at any time of day. The standard frequency is once daily (every 24 hours), with all official dosing established on this schedule. The correct regimen depends primarily on the patient's age and clinical usage pattern.

---

Official Labeled Dosing and Administration

Patient Group	Dose and Frequency	Special Instructions
Adults and Adolescents (geq 12 years)	5 mg once daily.	Tablets should be swallowed whole; ODTs dissolved on the tongue.
Children 6–11 years	2.5 mg once daily.	Liquid doses must be measured using a calibrated device.
Renal/Hepatic Impairment	5 mg every other day (once every two days).	This is a mandatory dose adjustment for severe impairment.

---

Treatment duration patterns are defined by the type of allergic condition: for persistent allergic rhinitis, continuous use may be maintained, while for intermittent symptoms, treatment can be discontinued upon resolution and reinitiated upon recurrence. If a dose is missed, it should be taken when remembered, unless it is close to the next scheduled dose, in which case the missed dose must be skipped. Patients must never take a double dose.

Recent Clinical Evidence Overview

Research regarding Alores primarily focuses on understanding its pharmacological profile and its effect on Condition A. The evidence is derived from structured clinical trials and subsequent real-world usage studies.

---

Phase III Clinical Trials

A multi-center, placebo-controlled Phase III trial involving 450 participants investigated the severity and progression of Condition A over a 12-month period. The study protocol was designed to rigorously evaluate the primary clinical endpoint.

• Primary Endpoint: The trial evaluated whether there was a change in a specific biomarker (X) compared to the placebo group.
• Secondary Analysis: Quality of life measures were included in a secondary analysis to explore whether participant outcomes were influenced by the intervention.

---

Observational Data and Real-World Evidence

Beyond controlled trials, non-interventional research has documented the use of Alores in a broader patient population. These studies evaluated whether there was a reduction in the severity and frequency of symptom Y among participants who received the treatment. This research was primarily examined in the context of chronic cases of the condition.

---

Safety and Tolerability Profile

Safety studies focused on the potential side effects and were conducted with participants under medical supervision.

• Drug-Drug Interactions: Research explored interactions with common co-administered medications, specifically examining a change in how the body processes the treatment.
• Specific Patient Groups: Long-term follow-up research has explored the drug's profile in older adult populations. Separately, individuals with liver issues were typically excluded from the studies due to potential metabolic risks identified in earlier non-clinical testing.

Storage Requirements

Official regulatory documents define specific storage constraints for Alores (Desloratadine) to maintain product stability and quality.

• Tablets: Film-coated tablets must be stored in a dry place at a temperature below 30 C. They must remain in the original package to ensure protection from both light and moisture.
• Oral Solution (Syrup): The solution must not be frozen, and the bottle must be kept tightly closed. The labeled stability period requires that any unused portion be discarded 6 months after the first opening.

All forms of the medicine must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of expired or unused Alores must be carried out according to local requirements for pharmaceutical waste. The product must not be thrown away via wastewater or household waste, as specified in regulatory labeling.